1. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer;Cunningham;N Engl J Med,2004
2. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer;Van Cutsem;J Clin Oncol,2007
3. Koehne C. Cetuximab plus FOLFIRI first-line in metastatic colorectal cancer (mCRC): the randomized phase III CRYSTAL trial. 9th World Congress on Gastrointestinal Cancer Annual Meeting, Barcelona, Spain, 2007; (Abstr O-0031).
4. Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial Sobrero A. 14th European Cancer Conference, Barcelona, Spain;Scheithauer,2005
5. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry;Chung;J Clin Oncol,2008